Dr Abdul Mannan: Patient Has CAPS with 7000 Platelets – Do You Anticoagulate?
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Platelets 7,000. Your patient has CAPS (Catastrophic Antiphospholipid Syndrome). Do you anticoagulate?
This is the dilemma every haematologist dreads.
Catastrophic APS (CAPS) throws you into a perfect storm: sky-high thrombotic risk meets dangerous bleeding territory. The instinct is to anticoagulate aggressively. But at 7,000 platelets, that can be fatal.
Here’s the “Bridge to Anticoagulation” approach:
Step 1: HOLD and TRANSFUSE
Stop therapeutic anticoagulation
Give platelet transfusions (unlike TTP, this is safe in CAPS)
Continue immunosuppression and plasma exchange
Step 2: Watch the Safety Window
Platelets <20k: Hold anticoagulation, continue triple therapy
Platelets 20-50k: Consider prophylactic dosing
Platelets >50k: Resume therapeutic anticoagulation
Step 3: Choose UFH
Short half-life, reversible with protamine
Avoid LMWH and warfarin initially
Rule out HIT if platelet recovery stalls
Fourth line: Eculizumab If platelets stay below 20k despite triple therapy, think complement-mediated microangiopathy. Eculizumab can be a lifesaver here.
The bottom line? Don’t let fear of thrombosis push you into fatal bleeding at 7,000. Build the platelet bridge first.
CAPS Task Force recommendations (2020) and real-world experience support this stepwise approach.
Have you managed CAPS with severe thrombocytopenia? What was your strategy?”

More posts from Dr Abdul Mannan on Hemostasis Today.
-
Jul 5, 2026, 04:54Saneha Anjum Shaik: What Every Clinician Should Know Before Ordering Blood Tests
-
Jul 5, 2026, 04:37Mathis Richter: How The Bone Marrow Responds To Myocardial Infarction Predicts Clinical Outcome
-
Jul 5, 2026, 02:45Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
-
Jul 5, 2026, 02:24Shreya Agarwa: Transforming Care For Adolescents With Heavy Menstrual Bleeding
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins